Due Diligence of course...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
no, not at all, was just curious when i saw the subject in the streamer
and if im not mistaken, anyone investors that own more than 5% of a firm's public shares must file a disclosure to their identity
GDAR
Progress in healing is slow. My diabetes and meds have slowed the wound healing down... My daughter has not left my side through all this. bless her heart. please continue to send great thoughts my way. hugz to all and I love you.
spent a few days in the hospital again... wasn't healing and had some gross issues. Sent me into tears... They have a wound vac in place and home health comes every other day to change the dressings. This too shall pass...hugz all
I am finally home, yay!!! 5 days in ICU and 2 days regular. Things went better than expected according to the drs. They really thought I would have more complications afterwards once the surgery was complete. They implanted the gastric stimulator, repaired the hernia in the Transverse colon, removed part of the ileum and ascending colons, removed my appendix... All complications are history, mostly due to my bad lungs and it's time to heal once again. thank you for all the prayers and thoughts. I love you all. Hot Mommas in the house!
Wow that is Awesome a/h GROC NEWS!!!ty for sharing
http://ih.advfn.com/p.php?pid=nmona&article=57248726
GROC
Wow that is Awesome a/h NEWS!!!
http://ih.advfn.com/p.php?pid=nmona&article=57248726
GROC
Implant Surgery is the 25th!!!! finally finally finally!!!! yayyyy I am so sick of being sick. It has been a very long year and the implant surgery got put on the back burner with the tumor. I am totally excited to eat again like normal people and put the ninja up, unless I want a margarita!!! lol hugz and thanks to all your prayers, Diva will be up again!!!
$GROC News-Great Rock Development Corp Updates Shareholders OAKVILLE,
Ontario, April
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=86756583
Wow Awesome News!!! ty for sharing
AMBS Amarantus Announces Preclinical Development Timeline for MANF Therapeutic
Last update: 4/11/2013 7:30:01 AM
SUNNYVALE, Calif., Apr 11, 2013 (BUSINESS WIRE) -- Amarantus BioScience Holdings, Inc. (otcqb:AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today provided a timeline of key activities and milestones related to the preclinical development of MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor). The Company is currently focused on developing MANF across three broad categories: Parkinson's disease and Traumatic Brain Injury; large systemic applications such as Ischemic Heart Disease and Diabetes; and orphan indications.
"We plan to move forward on a number of fronts this year with MANF, leading potentially to one or more Investigational New Drug (IND) filings in 2014," said Gerald E. Commissiong, President and Chief Executive Officer of Amarantus. "The pace and scope of activities outlined today reflect the unique properties of MANF, the positive results reported earlier this year in neuroprotective and neurorestorative animal models of Parkinson's disease and supportive data from the published literature."
The upcoming activities related to Amarantus' Parkinson's disease program include:
-- Create mammalian GMP production processes for MANF; the Company has sourced the expertise for these activities, and has started development of the supporting analytical and bioanalytical assays;
-- Form a partnership agreement in the third quarter of 2013 with a firm specializing in Convection-enhanced delivery (CED) of drugs to the brain;
-- Initiate non-human primate pharmacology studies in Parkinson's disease models in the second half of 2013 in order to establish an appropriate dosing regimen for human clinical studies;
-- Potentially evaluate MANF gene therapy based upon upcoming developments in the field of neurotrophic factors for Parkinson's disease, and the Company's current patent position whereby the Company owns exclusive rights to MANF gene therapy applications in all vector systems.
Additional planned activities are expected to include:
-- Conduct pharmacokinetic and pharmacodynamic (PK/PD) studies, with data available in the third quarter of 2013, to evaluate the biological properties of MANF when administered systemically, with data to be released as it becomes available;
-- Conduct pharmacology studies in traumatic brain injury, ischemic heart disease, diabetes and certain other animal models in the third quarter of 2013, with data to be released as it becomes available;
-- Evaluate MANF in a variety of animal models of orphan diseases in the third quarter of 2013 that represent significant market opportunities, and where there is limited or very limited competition;
-- Initiate MANF toxicology studies upon development of a master cell bank of MANF protein material as one of the final pre-IND steps;
-- File an IND in 2014.
"Based on our progress with these preclinical activities and the interest and level of data in specific indications, we will seek to partner with biopharmaceutical companies or appropriate not-for-profit disease foundations in order to accelerate our development program and assist in recruiting patients for future clinical studies," said Mr. Commissiong. "We will prioritize our clinical development programs based upon the outcome of the pharmacology studies that will begin in the third quarter of 2013 for the indications outlined here today. We intend to give highest priority to those indications where we have a shorter path to market, and where non-dilutive financing is available to support further development. Fortunately for the Company, it is likely that many of the pre-clinical studies will have applications across indications, meaning we will get the advantage of a particular set of data enabling multiple indications."
The Company will seek to gain 'Breakthrough,' 'Fast Track' and/or 'Orphan Drug Designation' status with the FDA where the Company believes the data generated justifies such a designation, potentially significantly reducing the time to market for MANF and/or improving the potential economic outcome for the Company.
The Company believes MANF could address the following very significant market opportunities:
-- Parkinson's disease: $1 billion
-- Traumatic Brain Injury: $200 million
-- Ischemic Heart Disease: $2 billion
-- Diabetes: $2 billion
-- Orphan diseases: $2 billion
Large pharmaceutical companies have shown significant interest in neurotrophic factors for Parkinson's disease for over two decades. In 1993, Amgen acquired Synergen for $262 million shortly after Synergen successfully completed studies using GDNF as a protein therapeutic in animal models of Parkinson's disease. In 2007, Genzyme entered into a $150 million partnership with Ceregene to gain access to ex-U.S. marketing rights to Neurturin after Ceregene successfully completed a Phase 1 clinical study demonstrating safety for Neurturin as a gene therapy product. Ceregene is expected to announce data on a recently completed Phase 2 study this quarter.
The acute ischemic heart disease market represents an $8 billion market worldwide. The chronic ischemic heart disease market represents a $30 billion market. One of the key unmet medical needs in the ischemic heart disease market is limiting ischemia/reperfusion associated with myocardial infarction, the area where MANF has shown significant promise in the published literature.
Diabetes represents a $28 billion market worldwide. One of the key unmet needs in the diabetes market is improving beta cell function, an area where MANF is believed to hold promise.
A prime example of a successful orphan strategy is Genzyme, who was successful in turning its orphan drug strategy into a $20.1 billion buyout by Sanofi Aventis in 2011. Another example of a successful orphan strategy is FerroKin Biosciences, which was successfully acquired by Shire for $325 million in early 2012 with only $27 million in paid-in-capital and a virtual staff of seven employees. In 2011, Alexion Pharmaceuticals reported $783 million in revenue based on sales of its only product Soliris, a drug that treats a population of approximately 10,000 patients in the U.S. and Western Europe.
About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)
MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (Programmed Cell Death). Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (in response to injury or disease), via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics. MANF's current lead indication is Parkinson's disease with additional focus on Traumatic Brain Injury (TBI). Future indications may include myocardial infarction and certain rare and ultra-rare orphan diseases where MANF is currently being evaluated.
About Amarantus
Amarantus is a development-stage biotechnology company founded in January 2008. The Company is focused on developing unique products and proprietary technologies for the potential treatment and/or diagnosis of Parkinson's disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for neurological disorders where there is a significant unmet medical need. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and related nervous-system disorders. For further information please visit .
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible progress of the MANF technology in testing for Parkinson's disease, statements about expectations, plans and prospects of the development of Amarantus' diagnostic product candidates for Alzheimer's and Parkinson's disease, traumatic brain injury, ischemic heart disease, diabetes, and unspecified Orphan indications; and the potential market size for the LymPro test for Alzheimer's disease. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks associated with development of therapeutic drug candidates, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.
SOURCE: Amarantus BioScience Holdings, Inc.
Investor/Media Contact
LHA
Don Markley, Senior Vice President
310-691-7100
dmarkley@lhai.com
Copyright Business Wire 2013
updated ss in ibox, otc recently updated the numbers:)
GM all, the dr handed me FDA info on the Gastric Pacemaker yesterday that he is gonna implant. 10 pages and said, you prolly won't understand any of this... LOL well anyways. I have to clear respiratory on Monday since everything is putting pressure on my organs, walk 2 doors down to the surgeons office with the consent forms and they will schedule me for the surgery. He is also gonna do some mesh repair... and off to the races we go once again. Get my steak dinner and salad ready boyz and girlz!!! :) Prayers for Diva are welcome. love you guyz
Good Morning GROC wonderful peeps:)
Hello loves, see the surgeon this morning:) say a prayer love you all:)
Good Morning! sizzling HOt!!!!
GROC
Good Morning GROC er's:) Happy Easter!
BIO updates, Tuesday March 26,2013
Opexa Therapeutics Inc. (NASDAQ:OPXA) shares gained 27.01% to $2.70 on no official news. The company, on Feb. 27, said it received written communication from Nasdaq giving the company until May to become compliant with listing regulations. The company received notification from Nasdaq Listing Qualifications Staff in November that its stockholders equity of $2.3 million reported for the period ended Sept. 30 was below the required $2.5 million. Nasdaq gave Opexa until Jan. 10 to meet the equity requirement, but the company filed for an extension.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares plunged 61.60% to $1.97 after the company announced today that its Phase 3 trial of palifosfamide (ZIO-201) for the treatment of metastatic soft tissue sarcoma in the first-line setting (PICASSO 3) did not meet its primary endpoint of progression-free survival (PFS).
The study's independent data monitoring committee (IDMC) has recommended that patients be followed for overall survival (OS), the study's secondary endpoint, however the Company does not expect to continue follow up for OS. Palifosfamide was well tolerated, with a safety profile in combination with doxorubicin observed in the study comparable with other palifosfamide clinical trials in soft tissue sarcoma.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares gained 0.35% to $8.56. The company, on Mar. 4, said it lost $21.3 million in the fourth quarter, compared to $23.7 million of 2011. Total interest and other expense in the fourth quarter of 2012 decreased to $1.0 million, compared to $5.4 million in the fourth quarter of 2011. Total interest and other expense in the full year ended December 31, 2012, increased to $28.4 million, compared to $26.4 million in full year ended December 31, 2011.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares increased 15.76% to $5.95. The company on Mar. 15 announced its earnings results. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.30. The company posted revenue of $8.87 million for the quarter, compared to the consensus estimate of $1.16 million.
Amarin Corporation plc (ADR) (NASDAQ:AMRN) stock dropped 5.95% to $6.90. The company, on Mar. 7, announced that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/614,111titled "Stable Pharmaceutical Compositions and Methods of Using the Same."
Additionally, the company, on Feb. 28, reported a fourth quarter GAAP net loss of $10.6 million, or basic and diluted loss per share of $0.07. Fourth quarter Non-GAAP adjusted net loss was $42.0 million, or non-GAAP adjusted basic and diluted loss per share of $0.28.
checking everyday for news updates for GROC, I am excited... wanna come back with 100?
I am watching for GROC to go current, anyone know how long it takes after the attorneys letter comes out usually?
http://ih.advfn.com/p.php?pid=nmona&article=56847247
Hey AMA, nice to see you on the GROC board:) cheer's my friend
how long does it usually take after the attorney letter does the otc info update? can't wait to see what GROC has up it's sleeve!
HOPE video for Diva!!! hanging in there, see surgeon again on the 9th for pre-lims on next surgery. Hoping its the last for awhile:) time to implant the stomach stimulator so Diva can have her steak dinner!!!
This is what I have been going through the last year, just like this lady.... HOPE!!! and tons of PRAYERS!!!
BIO updates, Monday March 25, 2013
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic solutions, announced it received the CE Mark for its Quidel Molecular Direct HSV 1+2/VZV assay for the differentiation and detection of herpes simplex viruses 1 and 2 (HSV 1+2) and varicella-zoster virus (VZV) in active lesions.
Quidel's new PCR assay kit distinguishes between three infectious diseases: HSV 1, the virus responsible for most cold sores and some genital herpes transmissions; HSV 2, the virus primarily responsible for most genital herpes and some cold sores; and VZV, the virus responsible for chicken-pox in children and shingles among adults.
Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Stivarga® (regorafenib) tablets for the treatment of patients with metastatic colorectal cancer (mCRC).
In September 2012, Stivarga was approved by the U.S. FDA for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. It was approved by the U.S. FDA for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate in February 2013.
Stivarga is a Bayer compound developed by Bayer and jointly promoted by Bayer and Onyx in the United States. In 2011, Bayer entered into an agreement with Onyx, under which Onyx receives a royalty on all global net sales of Stivarga in oncology.
The approval of Stivarga by the MHLW is based on data from the international multicenter pivotal Phase III CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial which evaluated regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients with mCRC, whose disease has progressed after approved standard therapies. The CORRECT study included 20 sites in Japan.
CANTEL MEDICAL CORP. (NYSE: CMN), through its Mar Cor Purification subsidiary, has continued the expansion of its water purification and filtration unit with the purchase of the hemodialysis water business from Siemens' Water Technologies business unit.
Mallinckrodt, the Pharmaceuticals business of Covidien (NYSE: COV), today announced that it launched the 36 and 54 milligram (mg) dosage strengths of Methylphenidate HCl Extended-Release (ER) Tablets USP (CII), generic version of CONCERTA®.
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin* was recently submitted to the Food and Drug Administration (FDA) in the United States for the treatment of type 2 diabetes mellitus (T2D) in adults.
InSite Vision Incorporated (OTCBB: INSV) today announced that the last patient has completed dosing and evaluation in the DOUBle Phase 3 clinical trial of AzaSite Plus™ and DexaSite™ for the treatment of blepharitis.
MMRGlobal, Inc. (OTCQB: MMRF) ("MMR"), a leading provider of Personal Health Records ("PHRs"), MyEsafeDepositBox storage solutions and electronic document management and imaging systems for healthcare professionals, today announced the launch of seamless connectivity between the MyMedicalRecords Personal Health Record and Electronic Medical Record ("EMR") systems in medical clinics starting April 15, 2013.
NeuroVive, (NASDAQ :NVP) a leading mitochondrial medicine company, announces that its shares have been approved for listing on NASDAQ OMX Stockholm by the exchange's Listing Committee.
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that it has received notification that their patent and trademarks for its Nyloxin™ line of pain relievers have been published in India's Official Journal.
Pfizer Inc. (NYSE: PFE) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved XELJANZ® (tofacitinib citrate) for the treatment of adults with rheumatoid arthritis (RA) who have had an inadequate response to existing therapies.
Fortissimo™ -- a voice-activated and hands-free speakerphone from Chattanooga's Clarity, a division of Plantronics (NYSE: PLT) -- is one of 15 innovations selected as a 2013 da Vinci Awards® finalist.
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic solutions, announced today that it received the CE Mark for its Quidel Molecular Direct HSV 1+2/VZV assay for the differentiation and detection of herpes simplex viruses 1 and 2 (HSV 1+2) and varicella-zoster virus (VZV) in active lesions.
Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that it will acquire SARcode Bioscience Inc., a privately held biopharmaceutical company based in Brisbane, California.
Vycor Medical, Inc. (OTCBB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced it has been issued patent number 10106385.8 for its ViewSite™ Brain Access System ("VBAS") for the Hong Kong market.
Thank you, have to stay positive:) only way I am gonna beat this thing!
GM, yes starting to get some attention, I am watching for sure how she develops
GROC
GM, gotta love the buzz!
GROC
Awesome job!!!!!
According to the Attorney letter with Respect to current information The Company underwent a 50:1 reverse split of its common stock on January 9,2011 reducing its number of outstanding shares from 202,509,180 to 4,050,183
Then on November 16, 2012
75,000,000 restricted common shares were issued to a conversion of a note.
There are currently 105,050,183 GROC common shares outstanding.
Mar 15, 2013 period ending Dec 31, 2012
http://www.otcmarkets.com/financialReportViewer?symbol=GROC&id=100950
Nothing is said about Authorized. The only thing I have found so far is their website states:
Publicly traded under ticker: GROC
Shares Outstanding: 109.000.000
Authorized: 275,000,000
anyone find anything different? I will keep reading
took me a sec, found-website!!! http://www.greatrockdev.com yayyy I still have the touch:) interesting, reading financials now on GROC
marked board, looks like I'd better keep a watchful eye on you boyz:)
Holy Cow!!! what's going on over here on GROC boyz:)
you are so welcome:)
#308 :)
#190 for you, cheer's
#116, cheer's :)
#38 :)
#211 for you, Cheer's :)
HITR dd Hitor Group - Green Technology
HITR Business Description
(OTCQB: HITR) (BERLIN: HTO)
Hitor Group is an industry leading Environmental Technology Accelerator that delivers best-in-class 'green' technology solutions for a better world. Hitor applies capital and best-in-class business practices to integrate green technologies, expand distribution channels, and catalyze rapid and profitable growth. Synergistic and proprietary technologies that can provide viable economic solutions to serve commercial markets along with developing communities are sourced worldwide. The global demand for solutions to these challenges has never been greater and at the same time innovations in technologies for solutions have arrived. Our goal is to bring these applications to this growing market segment and create shareholder value. To learn more about The Hitor Group, please visit our website at http://www.hitorgroup.com
Feb 2013 Hitor Group presentation with latest technologies:
http://www.hitorgroup.com/wp-content/uploads/2012/03/Hitor-Technologies-February-2013-.pdf
HITR Contact Info
6513 132nd Ave. N. E.
#376
Kirkland, WA 98033
Phone: (425) 788-9823
Email: info@hitorgroup.com
HITR Management
The Hitor management team and advisory board brings years of business expertise across a broad range of disciplines that account for over hundreds of millions of value creation for shareholders, business partners and customers. The Hitor team averages 30+ years of experience in developing and marketing disruptive technologies that include communications, transportation, construction, recycling and green technologies. The team has extensive transportation, construction and development related experience as well as international businesses development and negotiating with foreign governments.
Ken Martin
Position: Director and Chief Executive Officer
Ken Martin is the Director and Chief Executive Officer of Hitor Group. Mr. Martin, founder of International Telcom Solutions, Inc. (ITS) has an extensive international background in the telecommunications industry spanning fifteen years. Through a vast global network Mr. Martin negotiates government level contracts for VOIP (Voice over the Internet Protocol). To date he has initialized contracts for Russia, Germany, Poland, Ukraine, Italy and Malta. Current negotiations underway include Thailand, Viet Nam, Lebanon, Turkey, Jordan, France, Cyprus, China, and former Russian States. He is also the owner of a telecommunications company and the founder of an International telecommunications company since 1992. He has negotiated multi-million dollar contracts with governments and major companies.
Ric Harris
Position: Director and President
Mr. Harris brings over 35 years of business experience in technology, financing, sales & marketing as well as private and public company development experience. Ric is also CEO of AsiaCan an International Investment Company based in Shanghai. Ric has been consulting with a wide variety of financial and technical companies (Royal Bank of Canada, Canada Trust, Oracle and many other Fortune One Thousand Companies) for decades and brings a wealth of International Contacts.
Read more on the Management Team: http://www.hitorgroup.com/about-us2/
HITR Technologies
1) Patented Tire Recycling Technology
2) Patented Ceramic Composite Technology
3) Proprietary Steel Manufacturing & Panel Framing Process
Construction
Nearly a billion people live in a slum and that number is expected to double in the next 25 years. (UN-HABITAT: 2006)
Hitor Construction is in the business of building high quality, durable low cost houses. There is an incredible shortage of good quality adequate housing around the globe. The Hitor Construction housing solution addresses this need and is poised to become one of the leaders in the prefabricated housing market.
We have integrated patented building technologies that allow us to manufacture hundreds of homes a day per manufacturing plant to help address the current demands. Hitor’s goal is to open up hundreds of manufacturing plants around the world helping to not only stimulate the economy, create jobs, but more importantly provide solid homes for those in need. Basically our homes are customizable to any size, any climate, and any building requirements.
The Hitor Construction difference is:
*Lifetime homes completely customizable and expandable to individual / regional specifications, codes, regulations and conditions.
*Permanent homes delivered to building site, erected in hours with minimum local unskilled labor – creates jobs locally
Rugged panels
*Fire-resistant – concrete coated with drywall or plaster on the interior.
*Vibration-dampening design – with stand extreme winds, quakes and tremors (can be bolted or suspended or even on stilts).
*CST construction – resists bugs and rodents.
Thermal resistance of R20.
*Saves time & money with no material waste.
*Available 100% “Turn Key Home” or can integrate with local builders for plumbing and electrical as well as with local building manufacturers for doors and windows if necessary.
*Most efficient manufacturing process available to date.
Tire Recycling Technology
Hitor has identified an exciting new technology that will help to minimize the billions of tires being dumped annually and polluting land fills in every country in the world.
Hitor is completing a Joint Venture Agreement with a Nano Technology partner that has created a patented process that produces new construction products from recycled tires.
The process uses Nano particles of rubber to produce a new ‘Wood Replacement Product’ using micronized rubber for process intensification; this gives an almost endless range of final indoor / outdoor products, all of which are infinitely recyclable using the same processes that created them in the first place.
Hitor is currently in final negotiations with several countries wanting to build a Hitor manufacturing plant utilizing the Tire Recycling technology to produce affordable & durable housing for their citizens.
Benefits to NanoParticle Technology Products:
1) Environmentally safe,
2) Resistant to UV rays, salts of all types, water, chemicals and all types of weather,
3) Durable, impact proof and colour safe,
4) Mildew, mould and insect resistant,
5) Sound proofing, insulative value.
Pre Fabricated Steel & Concrete
Hitor Group Inc. has developed a Joint Venture agreement working with New Future Building utilizing a proprietary process utilizing pre fabricated steel and concrete building solutions to build multifamily homes world wide. New Future brings decades of project management, building design, development and construction management experience to the joint venture.
New Future’s management team has a track record of developing and building quality new communities throughout Western Canada. Based in Kamloops, the company has built hundreds of homes, including a mix of retirement care facilities, town homes, apartments and buildings.
Mike Rink CEO
Mr. Rink brings with him over 35 years of construction experience from hands on carpentry to design, construction and completion of hundreds of homes, office buildings and senior citizen housing. He owns and runs a 25-person corporation that is capable of completing all aspects of building design, architecture, engineering, drawings, and site management all the way to completion. He has in-house architects, engineers, technologist, and project and construction managers who assist in every aspect of building. New Future specializes in creatively solving housing needs by utilizing proprietary prefabricated steel and concrete panel solution coupled with many of the other Hitor technologies.
Ceramic Composite Cold Spray
The demand for Composite Ceramic Coatings for solutions in the fields of Sustainable Housing, Concrete Surfacing, Heat Resistant Applications, Transportation, Oil & Gas and Waste Management & Containment present great opportunities in the market at this time.
NuGuardTM coatings are highly effective when used on infrastructure such as piping, boilers, high traffic surfaces and other equipment surfaces requiring additional protection. It gives industrial equipment, parts, and components a durable finish that provides complete protection from the elements that cause damage and premature wear.
NuGuardTM can be applied on the inside and outside of most materials to create a flawless barrier between the part and the corrosive and damaging elements that compromise performance, safety and the bottom line.
NuGuardTM also provides the superior reduction of radiated heat compared to other ceramic coatings on the market. Reduced heat prolongs the life of equipment and parts by reducing the stress and damage that naturally occurs when subjected to high and varying temperatures. The benefits of NuGuardTM in industrial settings include:
*A 5 to 10 fold increase in the life expectancy of equipment and parts;
*Enhanced performance of equipment, parts, valves and components;
Chemical attack protection;
*Corrosion and erosion protection;
*A reduction of radiated heat;
*A thermal layer of protection (insulation);
Increases the tinsel strength;
*Cold spray application – saves time and money;
*A smooth surface easy to maintain
NuGuardTM is a cold spray ceramic coating that can be applied to equipment surfaces to increase strength and protect components from the effects of temperature, erosion, abrasion and corrosion. It is commonly applied in a thin coating (1/16” to 1/8” or thicker) depending on the application.
Below are sample sections of a wall panels coated with Ceramic Composite. For the first time ever you now have a light weight, durable easy to install panel with the strength of steel.
Additional Technologies:
Nano-Jet
Hitor has spent the last 5 years researching and developing products that support the elimination of emissions, recycling and fuel savings. The ‘Nano-Jet’ is an efficient fuel saving emission reduction product. The newest patented version is being extensively tested in Europe and has produced exceptional results in almost every type of engine.
The new NanoJet:
*Dramatically reduces emissions,
*Reduces maintenance costs,
*And significantly reduces fuel consumption,
*Manufactured in Germany by Micfil.
Micfil International is Hitor’s technology manufacturer in Germany producing not only the the oil filtration system but as well overseeing the manufacturing of the Nano-Jet products.
http://www.micfil.com
Wind Turbine
Hitor has signed a manufacturing and distribution agreement with Vbine Energy that has patented a Vertical Axis Wind Turbine (VAWT), which is a leading technology in a new generation of vertical wind turbines that make reliable use of wind and updrafts to convert mechanical energy into usable power.
The VAWT incorporates a Permanent Magnet Generator that is powered by a set of uniquely-designed and mounted, patent-protected rotor blades that produce self-sustaining power where it is needed. The VBINE 5 KW VAWT is ideal for niche small wind rural and urban applications, such as housing development, remote telecommunications tower networks, building rooftops, farms, airports and other existing infrastructure. No to low maintenance, because there is no drive shaft or gear box, plus there are no brushes, bushings or slip rings to wear out, only 2 long-life sealed bearings to be occasionally greased and are expected to give 20-30 years of life.
What differentiates us from other vertical axis turbines?
*No drive shaft or gearbox
*No brushes or bushings or slip rings (no moving parts except 2 long life bearings)
*Patented blade design that truly self starts in low wind yet captures the horse power out of the high wind
*A unique patented blade configuration to capture maximum power on smallest swept area
*Each blade produces power on 180 degrees out of the 360 degree rotation
*The center shaft does not rotate allowing for easy stacking of turbines on a single tower
*Extreme durability – little or no maintenance for 20+ years.
Click here to view a video of the wind turbine in action:
http://www.hitorgroup.com/wp-content/uploads/2012/03/VBine-Wind-Turbine.m4v
Water Filtration
Rounding out the necessary ‘green technologies’ is the latest in reverse osmosis water filtration. Hitor has partnered with a manufacturer of the leading patented water filtration systems in the world.
“Hitor is incredibly excited, as this new technology can treat almost any water source turning it back into 99.9% drinkable water… this truly will impact people around the globe.” Ken Martin CEO Hitor Group.
Hitor has recently signed a joint venture agreement white labeling a private patented water filtration company can produce quality approved water from virtually any contaminated water source. Not only does it have applications in world housing but in farming, resources, agriculture, building, mining and all municipal water treatments around the world.
This technology works in all areas like municipal water and sewage applications, animal waste lagoons, industrial wastewater extraction etc.
Hitor’s systems remove up to 99.9% of the natural or man-made pollutants found in these waters, rendering pure and renewed water for potable consumption or non-potable disposal (environmentally-suitable discharge).
Hitor with its green solutions will impact our way of life for years to come.
HITR chart:
HITR Share Structure
Common stock, $.001 par value, 100,000,000 authorized,
69,231,218 and 65,688,218 shares issued and outstanding
as of 10-Q/A received Jan 10, 2013 period ending Jun 30, 2012
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9013627
Headlines
http://finance.yahoo.com/q/h?s=HITR+Headlines
*Mar 13, 2013 Hitor Group, Inc. Executes Licensing Agreement in Pakistan
double check me please, not feeling the best:)